Stem-like exhausted CD8 T cells in pleural effusions predict improved survival in non-small cell lung cancer (NSCLC) and mesothelioma.

Background

Anti-tumor CD8 T cells are important for immunity but can become 'exhausted' and hence ineffective. Tumor-infiltrating exhausted CD8

Methods

Pre-treatment malignant pleural effusions (PEs) from 43 NSCLC (41 non-squamous, 2 squamous) patients were analyzed by flow cytometry. The percentages of Tex

Results

Higher frequency of Tex

Conclusions

This study demonstrates that PE CD8 Tex

Informations de copyright

2024 AME Publishing Company. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-284/coif). H.R. reports grants from IIRC post-doctoral fellowship (No. 224990-99, to H.R.) and post-doctoral training fellowship from the National Research Foundation of Korea (NRF-2020R1A6A3A03037852, to H.R.). T.F. reports serving as the board secretary of Mind the Change Inc. Y.C.G.L. is the current NHMRC Leadership Fellow and a recipient of the Investigator Grant (Leadership 2) (since July 2023), and the recipient of the Next Generation Clinical Research Practitioner Fellowship (from 2018 to June 2023). Rocket Med (UK) has provided free pleural fluid drainage kits for patients enrolled in randomized trials that Y.C.G.L. led. B.W.R. reports funding from the NHMRC of Australia, Insurance Commission of Western Australia, The US Department of Defense, Western Australian Department of Health, iCARE Foundation, Sir Charles Gairdner Research Advisory Committee, the Future Health Research and Innovation Fund scheme through the Biobank Interim Support Program 2021 and the Cancer Council of Western Australia. J.C. reports funding from the Australian National Health and Medical Research Council; The US Department of Defense; Insurance Commission of Western Australia; Western Australian Department of Health; iCARE Foundation; Sir Charles Gairdner Research Advisory Committee; Future Health Research and Innovation Fund scheme through the Biobank Interim Support Program 2021; Cancer Council of Western Australia. E.W.N. reports funding from the National Institutes of Health (NIH, Nos. R01CA264646 and R01AI176563 to E.W.N.), US Department of Defense, and Fred Hutchinson Cancer Center. And a cofounder, advisor and shareholder of ImmunoScape; an advisor and shareholder of Neogene Therapeutics; an advisor for NanoString Technologies and InduPro, and a shareholder in Trojan Bio. A.J.R. reports funding from The Australian National Health and Medical Research Council and The US Department of Defense. The other authors have no conflicts of interest to declare.